We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+35.2%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.01B
AUM Growth
+$314M
(+45%)
Cap. Flow
+$143M
Cap. Flow
% of AUM
14.12%
Top 10 Holdings %
Top 10 Hldgs %
64.85%
Holding
53
New
6
Increased
8
Reduced
14
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wave Life Sciences
WVE
|
+$111M |
| 2 |
Aclaris Therapeutics
ACRS
|
+$50M |
| 3 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
+$19.3M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$18.9M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$17.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Collegium Pharmaceutical
COLL
|
+$14.7M |
| 2 |
BLUE
bluebird bio
BLUE
|
+$14.3M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$12.6M |
| 4 |
Ardelyx
ARDX
|
+$9.17M |
| 5 |
TherapeuticsMD
TXMD
|
+$8.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACHN
1
DELISTED
Achillion Pharmaceuticals
ACHN
| $121M | 11.98% |
11,222,893
-510,922
| -4% | -$4.64M |
|
|
2
Wave Life Sciences
WVE
$1.12B
| $113M | 11.19% |
+7,088,651
| New | +$111M |
|
|
DYAX
3
DELISTED
DYAX CORPORATION
DYAX
| $102M | 10.12% |
2,717,618
+166,425
| +7% | +$5.35M |
|
|
SIOX
4
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $90.2M | 8.92% |
625,000
| – | – |
|
|
5
Aclaris Therapeutics
ACRS
$715M
| $69.1M | 6.84% |
+2,564,553
| New | +$50M |
|
6
TG Therapeutics
TGTX
$8.19B
| $33.6M | 3.32% |
2,813,779
-310,701
| -10% | -$3.92M |
|
|
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
| $33.2M | 3.29% |
2,253,237
+573,737
| +34% | +$7.71M |
|
|
8
BioCryst Pharmaceuticals
BCRX
$2.42B
| $31.9M | 3.16% |
3,094,064
+1,897,461
| +159% | +$18.9M |
|
9
Ascendis Pharma A/S
ASND
$16.5B
| $30.6M | 3.03% |
1,671,447
+210,179
| +14% | +$3.68M |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| $30.4M | 3.01% |
29,024
-4,641
| -14% | -$4.65M |
|
11
Coherus Oncology
CHRS
$217M
| $29.2M | 2.89% |
1,272,048
-32,972
| -3% | -$849K |
|
|
DRNA
12
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $28.8M | 2.85% |
2,428,571
| – | – |
|
|
13
Collegium Pharmaceutical
COLL
$1.18B
| $23.6M | 2.33% |
857,683
-695,492
| -45% | -$14.7M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $23.1M | 2.29% |
878,348
| – | – |
|
15
Protara Therapeutics
TARA
$214M
| $22.9M | 2.27% |
36,923
-749
| -2% | -$439K |
|
|
SBBP
16
DELISTED
Strongbridge Biopharma plc.
SBBP
| $20.4M | 2.02% |
+2,690,702
| New | +$19.3M |
|
17
Neurogene
NGNE
$672M
| $20.2M | 2% |
80,999
+4,391
| +6% | +$1.16M |
|
|
SGMO
18
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $20.2M | 2% |
2,212,036
+766,606
| +53% | +$5.91M |
|
|
CDTX
19
DELISTED
Cidara Therapeutics
CDTX
| $20.1M | 1.99% |
58,711
-318
| -0.5% | -$95.5K |
|
20
Arcturus Therapeutics
ARCT
$165M
| $19M | 1.88% |
433,273
+171,429
| +65% | +$7.72M |
|
|
ARNA
21
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $16.6M | 1.64% |
+871,448
| New | +$17.8M |
|
|
GBT
22
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $14.8M | 1.46% |
457,142
| – | – |
|
|
AIMT
23
DELISTED
Aimmune Therapeutics
AIMT
| $14.6M | 1.44% |
790,200
| – | – |
|
|
DMTX
24
DELISTED
Dimension Therapeutics, Inc
DMTX
| $12.3M | 1.21% |
+1,087,930
| New | +$13.8M |
|
|
25
Ardelyx
ARDX
$1.24B
| $10.4M | 1.02% |
571,444
-492,569
| -46% | -$9.17M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q4 2015 Portfolio in Review
As of Q4 2015, RA Capital Management held 53 positions worth $1.01B, up 45% from $696M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
RA Capital Management deployed $143M of net new capital in Q4 2015, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Wave Life Sciences: 7,088,651 shares worth $113M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier.
On the sell side, the largest reduction was Collegium Pharmaceutical, an estimated $14.7M trimmed.
- RA Capital Management's largest Q4 2015 buy was Wave Life Sciences: 7,088,651 shares worth $113M.
- RA Capital Management added most to BioCryst Pharmaceuticals in Q4 2015, an estimated $18.9M increase.
- RA Capital Management's biggest Q4 2015 reduction was Collegium Pharmaceutical, cutting an estimated $14.7M.
- RA Capital Management fully exited bluebird bio in Q4 2015, selling an estimated $14.3M.
- RA Capital Management's ten largest holdings make up 65% of its $1.01B portfolio in Q4 2015.
- RA Capital Management opened 6 new positions and closed 16 in Q4 2015.
- RA Capital Management's portfolio value rose 45% quarter-over-quarter to $1.01B.
Based on RA Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.